MYC and T-cell non-Hodgkin lymphoma: The authors’ conclusion was that CHEK1, as well as Myc, work as targets for ixazomib in cancer, and chemotherapy protocols including anti-CHEK1 drugs may represent a new approach for T-cell lymphoma therapy.